Elotuzumab 300 MG Injection [Empliciti] — RxCUI 1726115
RxNorm drug concept · Semantic branded drug
RxCUI 1726115
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1726115
Official nameElotuzumab 300 MG Injection [Empliciti]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEmpliciti 300 MG Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)269 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Elotuzumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Empliciti targets a protein called SLAMF7 that sits on the surface of myeloma cells. Instead of directly poisoning cancer cells the way chemotherapy does, it wakes up your own immu...
- What exactly is Empliciti treating, and how is it different from chemotherapy?
- Before your infusion starts, you'll be given pre-medications — including a steroid, an antihistamine, and acetaminophen — to help prevent reactions. The infusion itself goes slowly...
- What should I expect during the infusion itself?
🕸️ Concept Web — How Elotuzumab 300 MG Injection [Empliciti] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Elotuzumab 300 MG Injection [Empliciti]
RxCUI 1726115 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Elotuzumab
1726104IN
-
Elotuzumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Empliciti
1726111BN
-
Empliciti
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Elotuzumab Injection
1726109SCDF -
Elotuzumab Injectable Product
1726108SCDG -
Elotuzumab Injection [Empliciti]
1726113SBDF -
Empliciti Injectable Product
1726114SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Elotuzumab Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Elotuzumab 300 MG Injection
1726110SCD -
Elotuzumab 300 MG
1726107SCDC -
Elotuzumab 300 MG [Empliciti]
1726112SBDC
-
Elotuzumab 300 MG Injection
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Elotuzumab 300 MG Injection
SCD · 1726110 -
Elotuzumab 300 MG
SCDC · 1726107 -
Elotuzumab Injection
SCDF · 1726109 -
Elotuzumab Injectable Product
SCDG · 1726108
Brand-Name Concepts
-
Elotuzumab 300 MG [Empliciti]
SBDC · 1726112 -
Elotuzumab Injection [Empliciti]
SBDF · 1726113 -
Empliciti Injectable Product
SBDG · 1726114 -
Empliciti
BN · 1726111
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 1726115 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00003-2291-11 | 1 VIAL, SINGLE-USE in 1 CARTON (0003-2291-11) / 1 INJECTION... | EMPLICITI | E.R. Squibb & Sons, L.L.C. | 2015-11-30 |
| 00003-4522-11 | 1 VIAL, SINGLE-USE in 1 CARTON (0003-4522-11) / 1 INJECTION... | EMPLICITI | E.R. Squibb & Sons, L.L.C. | 2015-11-30 |
Observed labelers:
E.R. Squibb & Sons, L.L.C. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9176 | Injection, elotuzumab, 1mg | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.